MedTrace Logo

Effect of Genetic Polymorphisms on the Clinical Response to SGLT2 Inhibitors in Heart Failure Patients

NCT06201000 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 282

Last updated 2024-02-07

No results posted yet for this study

Summary

Sodium-glucose cotransporter 2 (SGLT2) inhibitors have shown further reductions in heart failure hospitalization, cardiovascular events, and mortality, especially for heart failure patients.

The SGLT2 gene, also known as SLC5A2 (solute carrier family 5 member 2), is located on chromosome 16 and is responsible for encoding SGLT2.

Several SLC5A2 mutations alter SGLT2 expression, membrane location, or transporter function.

Several common genetic variations were found in the SLC5A2 gene that may affect the response to treatment with SGLT2 inhibitors.

Conditions

Interventions

DRUG

SGLT2 inhibitors (Dapagliflozin and Empagliflozin)

10 mg of dapagliflozin or empagliflozin

Sponsors & Collaborators

  • University of Florida

    collaborator OTHER

  • National Heart Institute, Egypt

    collaborator OTHER_GOV

  • Beni-Suef University

    collaborator OTHER

  • October 6 University

    lead OTHER

Principal Investigators

  • Rania Sarhan, PhD · Beni-Suef University

  • Neven Sarhan, PhD · Misr International University

  • Bassem Zarif, MD · National Heart Institute

  • Julio Duarte, PhD · University of Florida

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-12-27
Primary Completion
2024-07-01
Completion
2024-09-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06201000 on ClinicalTrials.gov